David W. Dougherty

ORCID: 0000-0002-1992-7530
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Economic and Financial Impacts of Cancer
  • Health Systems, Economic Evaluations, Quality of Life
  • Palliative Care and End-of-Life Issues
  • Clinical practice guidelines implementation
  • Global Cancer Incidence and Screening
  • Lung Cancer Treatments and Mutations
  • Advances in Oncology and Radiotherapy
  • Medication Adherence and Compliance
  • Patient-Provider Communication in Healthcare
  • Cancer Immunotherapy and Biomarkers
  • Electronic Health Records Systems
  • Telemedicine and Telehealth Implementation
  • Frailty in Older Adults
  • Cancer Treatment and Pharmacology
  • Multiple Myeloma Research and Treatments
  • Cancer survivorship and care
  • Bladder and Urothelial Cancer Treatments
  • Health and Medical Research Impacts
  • Patient Satisfaction in Healthcare
  • Cancer Genomics and Diagnostics
  • Lung Cancer Research Studies
  • Discourse Analysis and Cultural Communication
  • Ethics in Clinical Research
  • Safe Handling of Antineoplastic Drugs
  • COVID-19 and healthcare impacts

Cancer Institute (WIA)
2018-2024

Penn Center for AIDS Research
2023-2024

University of Pennsylvania Health System
2023-2024

University of Pennsylvania
2022-2024

eHealth Initiative
2024

Abramson Cancer Center
2024

University of Rochester Medical Center
2010-2023

Dana-Farber Cancer Institute
2019-2021

Harvard University
2019

The University of Adelaide
2019

<h3>Importance</h3> Financial toxicity (FT), unintended and unanticipated financial burden experienced by cancer patients undergoing care, is associated with negative consequences increased risk of mortality. Older (≥70 years) are at for FT, yet data limited on FT whether oncologists discuss their patients. <h3>Objective</h3> To examine the prevalence in older adults advanced cancer, its association health-related quality life (HRQoL), cost conversations between <h3>Design, Setting,...

10.1001/jamanetworkopen.2020.25810 article EN cc-by-nc-nd JAMA Network Open 2020-12-07
Meghan E. Sise Jose Ramon Santos Jason D. Goldman Katherine R. Tuttle J. Pedro Teixeira and 95 more A. F. Seibert Yiannis Koullias Joe Llewellyn S. P. Regan Yang Zhao Hailin Huang Robert H. Hyland Anu Osinusi Helen Winter Rita Humeniuk Henry N. Hulter Robert Gottlieb Dahlene N. Fusco Rita Birne Fernando F. Stancampiano Claudia R. Libertin Catherine B. Small Markus Plate Mark McPhail Rosa Ballesteros Rita Birne Luís Malheiro Gil Silva João Paulo Correia Ana Carlota Vida André Silva Antonio Carujo Moncef Belhassen‐García Jordi Carratala Fernandez Gabriela Abelenda-Alonso Josep M. Cruzado Alexander Rombauts Diego Sandoval Miguel García Deltoro Fransesc Puchades Gimeno Neus Gómez‐Muñoz Maria Martínez Roma Juan Horcajada Gallego Castañeda Pablo Padilla Urrea Silvia Rial Crestelo Sergio Santos Fernandez David Ramon Jose Susanna Benet Rosa Benítez Carmen Bracke Anna Chamorro Sergio España Fredzzia Graterol Gemma Lladós C. López Lourdes Mateu Roger Paredes Boris Rebollo Alba Romero Laura Soldevila Elena Abad Anna Chamorro Alba San José Álex Soriano Mark McPhail Nicholas Medjeral‐Thomas Suzana Margareth Lobo Igor Z. Abolnik Anjali Acharya Leland Allen Keith Bellovich Mary Jane Burton Miriam L. Cameron Gerard J. Criner Lii-Yoong H Criner Joseph Lambert Marium Rashid Heidi Shore-Brown George A. Diaz David W. Dougherty Nathaniel Erdmann Dahlene N. Fusco Jason D. Goldman William R. Berrington Christine M. Logar Nidyanandh Vadivel Allison Everett Gonzalez Suarez Maria Lourdes Robert Gottlieb Mezgebe Berhe Gates B. Colbert Christopher Hebert Ankit Mehta Cedric W. Spak Lorie Estrada Richard Vargas Jennifer H. Choe Alex Pham Lynn Mason

Few antiviral therapies have been studied in patients with coronavirus disease 2019 (COVID-19) and kidney impairment. Herein, the efficacy, safety, pharmacokinetics of remdesivir, its metabolites, sulfobutylether-β-cyclodextrin excipient were evaluated hospitalized COVID-19 severe In REDPINE, a phase 3, randomized, double-blind, placebo-controlled study, participants aged ≥12 years for pneumonia acute injury, chronic disease, or failure randomized 2:1 to receive intravenous remdesivir (200...

10.1093/cid/ciae333 article EN cc-by-nc-nd Clinical Infectious Diseases 2024-06-24

BACKGROUND Chest wall progression of breast carcinoma after failure salvage surgery, radiation, and chemohormonal therapy is a quagmire with limited therapeutic options. Because photodynamic (PDT) offers excellent results in cutaneous lesions, PDT may play role this indication. However, to the authors' knowledge, published data for subgroup patients using only commercially available photosensitizing agent, Photofrin, often show high treatment morbidity, limiting PDT's usefulness. The authors...

10.1002/1097-0142(20010101)91:1<1::aid-cncr1>3.0.co;2-p article EN Cancer 2001-01-01

Five Buffalo, New York physicians provided carbon copies of their written pharmaceutical prescriptions to the investigators. The patients were contacted by telephone and asked completely read label prescribed medication describe itself. It was found that nearly 10 per cent sampled (N=223) dispensed with some form error. Recommendation is made request bring currently used medications them on physician office visits.

10.1097/00005650-197301000-00008 article EN Medical Care 1973-01-01

More oncologists desire to treat their patients with immune checkpoint inhibitors (ICIs) in the inpatient setting as use has become more widespread for numerous oncologic indications. This is cost-prohibitive and institutions because of high drug cost lack reimbursement setting. We sought examine current practice ICI administration determine if which clinical scenarios it may provide significant benefit therefore be warranted regardless cost.We conducted a retrospective chart review adult...

10.1200/op.22.00256 article EN JCO Oncology Practice 2022-11-21

ASCO Standards are evidence-based standards to provide frameworks for best practices in cancer care, following the development process as outlined Policies and Procedures Manual . follow Conflict of Interest Policy Clinical Practice Guidelines other guidance (“Guidance”) provided by is not a comprehensive or definitive guide treatment options. It intended voluntary use providers should be used conjunction with independent professional judgment. Guidance may applicable all patients,...

10.1200/op.24.00216 article EN JCO Oncology Practice 2024-05-22

Drawing from insights communication science and behavioral economics, the University of Pennsylvania Telehealth Research Center Excellence (Penn TRACE) is designing testing telehealth strategies with potential to transform access care, care quality, outcomes, health equity, health-care efficiency across cancer continuum, an emphasis on understanding mechanisms action. Penn TRACE uses lung as exemplar model for screening treatment survivorship. We bring together a diverse interdisciplinary...

10.1093/jncimonographs/lgae011 article EN other-oa JNCI Monographs 2024-06-26

Introduction Carboplatin is widely used to treat lung cancer in the United States as an alternative cisplatin. Several studies have demonstrated that cisplatin-based regimen associated with a high frequency of thromboembolic complications. However, there has been limited investigation directly comparing risk events (TEEs) between cisplatin- and carboplatin-treated patients cancer. Methods All treated cisplatin or carboplatin at Wilmot Cancer Center, University Rochester 2011 2014 were...

10.1371/journal.pone.0189410 article EN cc-by PLoS ONE 2017-12-11

Whole-brain radiation therapy (WBRT) remains standard practice for cerebral metastases, either as monotherapy or in conjunction with surgery stereotactic radiosurgery (SRS).1 Although potential radiation-induced side effects after WBRT are well described, we report the first (to our knowledge) case of fatal leukoencephalopathy following and SRS boost.

10.1016/j.adro.2016.01.002 article EN cc-by-nc-nd Advances in Radiation Oncology 2016-01-01

PURPOSE: Cancer clinical trial accrual rates are low, and information about contributing factors is needed. We examined video-recorded interactions to identify circumstances under which patients potentially eligible for a at major cancer center were offered trial. METHODS: conducted qualitative directed content analysis of 62 recorded with physicians (n = 13) intermediate- or high-risk prostate 43). Patients screened observed coded the in 3 steps: (1) classification all as explicit offer,...

10.1200/jop.19.00444 article EN JCO Oncology Practice 2019-12-02

Abstract Background Financial toxicity, the material and psychological burden of cost treatment, affects 30–50% people with cancer, even those health insurance. The treatment can affect adherence and, ultimately, mortality. toxicity is a equity issue, disproportionately affecting patients who are racial/ethnic minorities, have lower incomes, &lt; 65 years old. Patient education about patient-oncologist discussions recommended as ways to address financial toxicity; however, research shows...

10.1186/s13063-021-05593-y article EN cc-by Trials 2021-09-17

Ineffective handoffs contribute to gaps in patient care and medication errors, which jeopardize safety lead poor-quality care. The project aims are develop implement a standardized handoff process using an electronic medical record (EMR)-based tool ensure optimal communication of treatment-related information for patients receiving cancer treatment between oncology nurses.A multidisciplinary team convened standard safe process. intervention was developed over series phases Plan-Do-Study-Act...

10.1200/jop.18.00245 article EN Journal of Oncology Practice 2019-04-04

The purpose of this paper is to provide an assessment the impact Enterprise-wide Risk Management (ERM) on trading activities financial institutions, with emphasis derivatives. This divided into three parts. first part looks at evolution ERM in terms its culture organization, risk coverage, measurement methodologies, technology and performance measurement. second application as it relates individual types such market, credit, business risks. concludes overview key factors that are critical...

10.7202/1105291ar article EN Assurances : 2000-01-01

e22037 Background: Financial toxicity, or the strain caused by paying for health care services, can undermine mental and QoL of patients (pts) in cancer care. This study examined associations FT with depression, anxiety, older pts advanced cancer. Methods: is a secondary analysis baseline data from Geriatric Assessment intervention conducted UR NCORP (URCC 13070; PI: Mohile). At baseline, were categorized as experiencing if they reported any one following: delaying medications due to cost,...

10.1200/jco.2018.36.15_suppl.e22037 article EN Journal of Clinical Oncology 2018-05-20

One of the most challenging clinical problems in oncology for patients, families, and clinicians is occurrence multiple symptoms. Unrelieved symptoms result decreased functional status quality life increased distress mortality (Cleeland et al., 2013; Flannery, Phillips, & Lyons, 2009; Reilly 2013). Although experience co-occurring well established as a frequently occurring issue, research establishing effective interventions has been minimal.

10.1188/18.onf.619-630 article EN Oncology nursing forum 2018-08-17

e13684 Background: Clinical trials are often terminated due to insufficient accrual, with only about 6% of patients enrolling into a trial. Trial enrollment rates even lower for Black patients. In 2021, we began recruitment clinic-based behavioral trial testing the effectiveness health equity communication intervention designed address patient cancer treatment cost concerns. This study involves and providers completing surveys before after video-recorded clinical interaction. We implementing...

10.1200/jco.2024.42.16_suppl.e13684 article EN Journal of Clinical Oncology 2024-05-29
Coming Soon ...